WednesdayJan 31, 2024 9:45 am

SuperCom Ltd.’s (NASDAQ: SPCB) PureProtect(TM) Domestic Violence Monitoring Solution is Designed to Help Prevent Tragic Outcomes and Associated Litigation

SuperCom is an electronic monitoring solutions developer and provider that offers the PureSecurity(TM) Suite, a comprehensive range of products that include a domestic violence monitoring solution, a GPS tracking platform called PureTrack(TM), a house arrest enforcement solution, and an inmate monitoring solution The company holds that its advanced domestic violence monitoring solution could play a vital role for enhancing public safety measures, particularly in light of a recent cases emphasizing the critical need for effective response in domestic violence situations An Illinois appellate court recently upheld a $3 million jury award to the estate of the late Vanessa Taylor, who…

Continue Reading

WednesdayJan 31, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Announces Successful Completion of SOC 2 Type 2 Audit to Further Commitment to Data Security

D-Wave's completion of the SOC 2 Type 2 audit makes it the first full-stack quantum computing provider to achieve this compliance The company is deeply committed to data security as customers adopt the production use of its quantum computing solutions Going forward, D-Wave will perform annual SOC 2 Type 2 assessments, making the latest report available to current and potential clients upon completing a nondisclosure agreement D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world's first commercial supplier of quantum computers, recently announced the successful completion of its SOC 2(R) Type 2 audit…

Continue Reading

TuesdayJan 30, 2024 1:55 pm

QualityStocksNewsBreaks — Astiva Health Featured in Bell2Bell Podcast

Astiva Health, which is rapidly making its mark in the Medicare Advantage Prescription Drug (“MAPD”) sector with its commitment to transforming personalized and comprehensive healthcare, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Tri T. Nguyen, the co-founder and CEO of Astiva Health, joined the program to offer insights into the company’s foundations and its unique business model. “Astiva was established in 2020, with our operations commencing on Jan. 1, 2021, in Orange County and San Diego. Recently, we’ve expanded our services…

Continue Reading

TuesdayJan 30, 2024 1:37 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Expands Sales Dominican Republic, Caribbean Markets with Grupo Cavel Order

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received a vehicle order from Grupo Cavel for the sale of EVs its Electric Motors dealerships located in the Dominican Republic and Caribbean. The order was for 20 CAMPUS EV cargo vans. According to the announcement, Grupo Cavel plans to order additional vehicles and will be establishing a sales and service distribution channel for Mullen’s lineup of commercial EVs in the two countries. Grupo Cavel is a key retail automotive group in the Dominican Republic and has existing relationships in vehicle sales, distribution, warranty and servicing throughout the Caribbean.…

Continue Reading

TuesdayJan 30, 2024 12:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company’s upcoming planned U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. According to the announcement, the company had a successful pre-IND meeting with FDA officials. Following the guidance provided in that meeting regarding the development and filing of the IND, the company submitted the application on Jan. 29, 2024. The company will now wait 30 calendar days before initiating any clinical trials, in compliance with FDA guidelines.…

Continue Reading

TuesdayJan 30, 2024 12:16 pm

QualityStocksNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Expands Sales of Wearable Alcohol Detection Devices to Australia, New Zealand

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has entered into an international channel partnership to begin sales in Australia and New Zealand for its SOBRsure(TM) platform. The partnership is with Drug Testing Business Success, the region's leading drug- and alcohol-testing service provider. According to the announcement, Drug Testing Business Success has impressive experience in the transdermal alcohol detection industry and plans to distribute SOBRsure through a coalition of suppliers and a dedicated e-commerce website focusing on the behavioral health and justice sectors. The partnership included a 90-day proof-of-concept period; SOBRsure is now available for sale and is in…

Continue Reading

TuesdayJan 30, 2024 10:30 am

GSMI Social Media Strategies Summit 2024 For Senior-Level Marketers

Social media marketing professionals, executives, businesses, and enthusiasts, are invited to attend the GSMI Social Media Strategies Summit 2024 being held as a virtual event on February 28-29, 2024. This virtual event will be attended by acclaimed social media industry leaders who will share their in-depth insights for creating winning digital marketing campaigns. SMSSummit is a coveted social media conference platform that benefits several industry verticals and businesses by targeting greater audience reach. The conference focuses on a targeted audience of decision-makers in the social media industry. Senior marketing professionals share their experience and knowledge of time-tested social media strategies.…

Continue Reading

TuesdayJan 30, 2024 10:07 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and sale of 13,333,334 shares of common stock (or common stock equivalents in lieu thereof); the stock is offered at a purchase price of $0.30 per share. In addition, CNSP agreed to issue Series A warrants…

Continue Reading

TuesdayJan 30, 2024 9:45 am

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) Suite Shows Importance Amidst Reports of Latest Microsoft Corporation Cybersecurity Attack

Cyber attacks can cost corporations millions of dollars, endangering critical sensitive information, causing major operational headaches, and affecting hard-won corporate reputations Microsoft recently announced detection of a cyberattack that compromised the company’s corporate emails – an attack found to be launched by a Russian state-sponsored group referred to as Midnight Blizzard Sekur Private Data Ltd. offers consumers, businesses, corporations, and governments, Swiss-hosted solutions for secure communications and secure data management without the use of third-party cloud services Cybersecurity attacks can cost corporations more than significant amounts of money – they can come with hidden costs like an increase in insurance…

Continue Reading

TuesdayJan 30, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline

An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS With plans to move forward on many fronts for the clinical development of CNM-Au8, 2024 looks bright for Clene Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered